DD106643A1 - - Google Patents

Info

Publication number
DD106643A1
DD106643A1 DD17394873A DD17394873A DD106643A1 DD 106643 A1 DD106643 A1 DD 106643A1 DD 17394873 A DD17394873 A DD 17394873A DD 17394873 A DD17394873 A DD 17394873A DD 106643 A1 DD106643 A1 DD 106643A1
Authority
DD
German Democratic Republic
Application number
DD17394873A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to DD17394873A priority Critical patent/DD106643A1/xx
Publication of DD106643A1 publication Critical patent/DD106643A1/xx

Links

DD17394873A 1973-07-12 1973-07-12 DD106643A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DD17394873A DD106643A1 (ja) 1973-07-12 1973-07-12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD17394873A DD106643A1 (ja) 1973-07-12 1973-07-12

Publications (1)

Publication Number Publication Date
DD106643A1 true DD106643A1 (ja) 1974-06-20

Family

ID=5493031

Family Applications (1)

Application Number Title Priority Date Filing Date
DD17394873A DD106643A1 (ja) 1973-07-12 1973-07-12

Country Status (1)

Country Link
DD (1) DD106643A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537608A2 (de) * 1991-10-11 1993-04-21 APOGEPHA ARZNEIMITTEL GmbH Verfahren zur technischen Herstellung von 2,2-Diphenyl-2-(2-ethyl-butoxy)-essigsäure-(2-dimethylamino-ethyl)-ester-hydrochlorid
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2011114195A1 (en) 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2014025569A1 (en) 2012-08-09 2014-02-13 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
WO2022115056A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537608A3 (en) * 1991-10-11 1993-06-16 Apogepha Arzneimittel Gmbh Process for the technical preparation of 2,2-diphenyl-2-(2-ethylbutoxy)acetic acid, 2-dimethylamino-ethyl ester
EP0537608A2 (de) * 1991-10-11 1993-04-21 APOGEPHA ARZNEIMITTEL GmbH Verfahren zur technischen Herstellung von 2,2-Diphenyl-2-(2-ethyl-butoxy)-essigsäure-(2-dimethylamino-ethyl)-ester-hydrochlorid
EP3178477A1 (en) 2008-03-27 2017-06-14 Chase Pharmaceuticals Corporation Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
EP4088717A1 (en) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2011114195A1 (en) 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN104603108A (zh) * 2012-08-09 2015-05-06 才思制药公司 哌啶鎓季盐
US9896416B2 (en) * 2012-08-09 2018-02-20 Chase Parmaceuticals Corporation Piperidinium quaternary salts
WO2014025569A1 (en) 2012-08-09 2014-02-13 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
WO2022115056A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine

Similar Documents

Publication Publication Date Title
AR201758A1 (ja)
AU476761B2 (ja)
AU465372B2 (ja)
AR201235Q (ja)
AR201231Q (ja)
AU474593B2 (ja)
AU474511B2 (ja)
AU474838B2 (ja)
AU471343B2 (ja)
AU465453B2 (ja)
AU465434B2 (ja)
AU450229B2 (ja)
AU476714B2 (ja)
AR201229Q (ja)
AU466283B2 (ja)
AU472848B2 (ja)
AU476696B2 (ja)
AR199451A1 (ja)
AU447540B2 (ja)
AU461342B2 (ja)
AR195948A1 (ja)
AR210729A1 (ja)
AR200256A1 (ja)
AU471461B2 (ja)
AR195311A1 (ja)